UK Annual Virtual Next-Gen Immuno-Oncology Conference, October 26-29, 2021 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "5th Annual Virtual Next-Gen Immuno-Oncology Conference-UK" conference has been added to ResearchAndMarkets.com's offering.

Our 5th Annual Next Gen Immuno-Oncology Virtual Congress to be held on 26 - 29 October 2021 would address the challenges and future directions in IO research.

The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in the development of ADC's, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in the development of ADC's, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy

Meet and network with experts from leading universities and industry sharing their knowledge on Preclinical and Translational Immuno-Oncology Developments, NextGen CAR-T Cell Therapy, Immune Checkpoint Inhibitors, Monoclonal and Bispecific Antibodies and more.

A platform to meet experts from Pharma, biopharma and biotech companies and increase your learning in Monoclonal and Bispecific Antibodies, Cell Therapy and Immune Checkpoint Inhibitors.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

What to Expect

Key Highlights

• Updates in development of ADC's and Bispecific Ab's
• Immune Checkpoint Inhibitors and Combinations
• Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
• Biomarkers and Personalized Medicine in IO
• CAR-T Cell therapy, TCR Based-Cell Therapy
• Tumor microenvironment and Oncolytic Viruses

Why Attend?

• Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
• Find out new case studies of immune-oncology projects in the development
• Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
• Explore the latest platforms and technologies on the market for development
• Discuss the best tool for your research in immune-oncology
• Share your work and achievements with your industry peers in the Poster Session

Who Should Attend:

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

• Monoclonal and Bispecific Antibodies
• Cell Therapy
• Immune Checkpoint Inhibitors

For more information about this conference visit https://www.researchandmarkets.com/r/vry8zc

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900